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The molecular epidemiology and genetic diversity of
the human metapneumovirus (hMPV) were characterized
for a 3-year period (2000–2002) from viruses that were
identified in South Africa. Two major genetic groups (A and
B) and 2 subgroups (1 and 2) of hMPV were identified, as
well as 2–6 possible genotypes within the subgroups. A
shift in the predominant group was documented in succes-
sive seasons. Whereas the F gene was relatively con-
served between subgroups, a high degree of variation was
observed in the extracellular domain of the G gene of the
virus. The G protein identities between groups A and B
were 45.1%–53.1% at the nucleotide level and 22.4%–
27.6% at the amino acid level. These results provide evi-
dence for the diversity of both surface glycoproteins of
hMPV in Africa, which may be a prerequisite to understand-
ing protective immunity against hMPV.
H
uman metapneumovirus (hMPV) is an important
cause of acute respiratory tract infections worldwide
in both children and adults (1–11). It causes annual epi-
demics during the winter-spring months in temperate
regions. Taxonomically, hMPV belongs to the family
Paramyxoviridae, subfamily Pneumovirinae, and is the
only known human pathogen of the genus
Metapneumovirus (1,12). Genetically, its closest relative is
the avian pneumovirus type C (1,13,14); however, clinical-
ly, it resembles the respiratory syncytial virus (RSV) (15),
a common respiratory pathogen classified in the family
Paramyxoviridae, subfamily Pneumovirinae.
Genetic studies on hMPV have demonstrated the pres-
ence of 2 distinct hMPV groups and subgroups within
these groups (2,4,7,10,14–18); more recently, evidence has
been shown that multiple lineages may exist (19,20).
Limited available data indicate that both groups can circu-
late in a single season with the possibility of the predomi-
nant group switching in successive seasons (2,4,17,21).
Genetic variation in the hMPV attachment glycoprotein (G
protein) indicates a high degree of nucleotide variation,
which results in amino acid changes (17–19). This
sequence variation within the hMPV G gene has been pos-
tulated to be due to immunologic pressure. Our study was
designed to examine the extent of genetic variation and the
circulation pattern of hMPV in a single South African
community in 3 consecutive years (2000–2002) by
sequence analysis of the 2 surface (F and G) glycoprotein
genes from South African strains.
Materials and Methods
Specimens
Nasopharyngeal aspirates were obtained from children
enrolled in a vaccine efficacy study that was conducted in
Soweto, South Africa (22). The samples were obtained
from children hospitalized for a lower respiratory tract
infection in a 3-year period (2000–2002). Samples were
stored at –70°C until processed for this study. Details
regarding the cohort of children, procedure for collecting
nasopharyngeal aspirate samples, and other viruses isolat-
ed from these samples have been published in part (22,23).
The samples used in this study were from the entire year
and not confined to samples obtained from the winter-
spring months. Because of resource constraints, we
sequenced a minimum of 30% of the hMPV-positive sam-
ples from each month; 92 (45%) of 206 hMPV-positive
samples were sequenced for the F gene, and 61 (30%) of
206 were sequenced for the G gene. All samples that were
sequenced for the G gene were sequenced for the F gene.
Viral RNA was isolated from the stored frozen nasopha-
ryngeal aspirate samples by using the QIAamp viral RNA
kit (Qiagen, Inc., Valencia, CA, USA) according to the
manufacturer’s instructions. The study was approved by
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hMPV Detection of F Gene 
A nested reverse transcription–polymerase chain reac-
tion (RT-PCR) assay to amplify a fragment of the hMPV F
gene was used to detect hMPV. RT-PCR was performed
with the SUPERSCRIPT One-Step RT-PCR kit
(Invitrogen, Carlsbad, CA, USA) with primers 5′-
ATGTCTTGGAAAGTGGTG-3′ (corresponding to
nucleotide position 3052–3069 in the NL/1/00 genome
accession no. AF371337) and 5′- CCATGTAAATTACG-
GAGCT-3′ (nucleotide position 3844–3862 in NL/1/00 in
genome) under the following conditions: 50°C for 30 min;
94°C for 2 min; 94°C for 30 s, 45°C for 45 s, and 68°C for
1 min for 35 cycles; 68°C for 7 min. 
The nested PCR was performed with primers 5′-TCAT-
GTAGCACTATAACT-3′ (nucleotide position 3130–
3149) and 5′-TCTTCTTACCATTGCAC-3′ (nucleotide
position 3794–3810) under the following conditions:
94°C for 2 min; 94°C, 48°C, and 72°C for 1 min for 30
cycles; and 72° for 7 min. The PCR product was analyzed
by electrophoresis on a 2% ethidium bromide–stained
agarose gel.
hMPV Detection of G Gene 
The G gene open reading frame (ORF) was amplified
with the following primers: HMPVGunivF: 5′-GAGAA-
CATTCGRRCRATAGAYATG-3′ (nucleotide position
6262–6285 of NL/1/00, GenBank accession no. AF371337)
and HMPVGunivR: 5′-AGATAGACATTRACAGTG-
GATTCA-3′ (nucleotide position 7181–7204) under the
following conditions: 50°C for 30 min; 95°C for 3 min;
94°C for 1 min, 59°C for 1 min, and 72°C for 2 min for 38
cycles; and 72°C for 7 min. The PCR product was analyzed
on a 2% ethidium bromide–stained agarose gel. When nec-
essary to increase the yield for sequencing, a nested PCR
was performed with the same primer set.
Sequencing of hMPV F and G Genes
The PCR product generated for both F and G genes was
purified with the QIAquick gel extraction kit (Qiagen,
Inc.) and sequenced in both directions by using the nested
primers for the F gene and the primers used for detecting
the G gene. The PCR product was sequenced by using the
BigDye Terminator Cycle sequencing kit (Applied
Biosystems, Foster City, CA, USA) on the ABI 310
Genetic Analyzer (Applied Biosystems).
Phylogenetic Analysis 
Nucleotide sequence alignments were generated with
the ClustalX 1.81 software (24). Phylogenetic analysis was
performed by using MEGAversion (2.1) (25). Strains from
the Netherlands, NL/1/00, NL/17/00, NL/1/99, and
NL/1/94 (GenBank accession nos. AF371337, AY304360/
AY296021, AY304361/AY296034, and AY304362/
AY296060, respectively) and Canada, CAN97-83,
hMPV13-00, CAN98-75, and hMPV33-01 (GenBank
accession nos. AY485253/AY145296, AY485232,
AY485245/ AY145289, and AY485242, respectively) were
used as prototypes of the 2 groups and subgroups. The
hMPV sequences for the F and G protein genes presented
in this article have been deposited in GenBank under the
accession numbers AY694693–AY694784 and AY848859–
AY848919, respectively.
Results
A total of 2,802 samples collected in the 3-year study
period were analyzed by RT-PCR for hMPV by amplifica-
tion of the F gene protein. hMPV was identified in 206
(7.4%) samples in the 3-year period. One hundred one
(9.6%) of the 1,057 samples from the year 2000, 82 (7.3%)
of 1,128 samples from 2001, and 23 (3.7%) of 617 samples
from year 2002 were positive for hMPV.
Molecular Epidemiology of hMPV
We examined the circulation pattern of hMPV during
the 3 years by sequencing part of the hMPV F gene and
performing phylogenetic analysis for 92 hMPV-positive
samples. These samples, numbering 40, 34, and 18 from
years 2000, 2001, and 2002 respectively, were distributed
over all the months when hMPV was identified and
accounted for ≈30%–100% of the samples from each
month. Phylogenetic analysis indicated 2 major groups (A
and B), each divided into 2 subgroups (1 and 2), causing a
complex circulation pattern over the course of the study.
Both groups A and B viruses cocirculated throughout the
study period. Of the 92 hMPV-positive samples that were
categorized, 56 (60.9%) of the viruses belonged to group A
and 36 (39.1%) to group B.
During the 2000 epidemic, subgroups B2 and A2 cocir-
culated, with 72.5% of the circulating viruses belonging to
subgroup B2. In 2001 subgroups A1, A2, and B2 cocircu-
lated. Subgroup B2 virus significantly declined (4 [11.8%]
of 34) in 2001 compared to 2000 (29 [72.5%] of 40),
p<0.0001. Subgroup A1 emerged as the dominant strain,
causing 67.7% of infections, compared to 20.5% observed
for subgroup A2 and 11.8% for subgroup B2. Subgroup A1
also dominated in 2002, causing 83.3% of infections, and
cocirculated with the emergent subgroup B1. 
Sixty-one (66.3%) of the 92 hMPV-positive samples
sequenced for the F gene were further sequenced for the G
gene (Figure). Phylogenetic analysis of both the F and G
gene nucleotide sequences also showed 2 major genetic
groups (A and B) that could be further divided into 2 sub-
groups (1 and 2). The existence of these 2 major genetic
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of bootstrap replicas into 2 major groups and 99%–100%
of bootstrap replicas into 2 minor subgroups). 
From the topology of the trees, subgroup B2 was the
most divergent. Although the South African hMPV clus-
tered with both Canadian and Netherlands prototypes, the
South African subgroup A1 virus clustered more closely
with the Canadian prototype.
From the topology of the tree and supported by strong
bootstrap values (70%–100%), the subgroups can be fur-
ther divided into genotypes. We attempted to group the G
sequences of the 4 subgroups into genotypes by using the
criteria previously described for RSV (26), in which
sequences were arbitrarily considered a genotype if they
clustered together with bootstrap values of 70% to 100%
(internal nodes at the internal branches). When these crite-
ria were used (only on South African isolates), subgroup
A1 could be divided into 5 genotypes, subgroup A2 into 2
genotypes, B1 into 2 genotypes, and B2 into 6 possible
genotypes. 
Genetic Variation in South African hMPV Isolates
The estimated nucleotide and amino acid identities
showed a high percentage of identity for the F gene and
more variability for the G gene (Table). The estimated
identities for the F gene between the 2 major groups, Aand
B, were 83%–85% at the nucleotide level and
93.2%–95.8% at the amino acid level. In contrast, the G
gene estimated identities were 45.1%–53.1% at the
nucleotide level and 22.4%–27.6% at the amino acid level.
There was also a higher percentage of identity between
members of the same group (e.g., A1–A2) for the F gene
than for the G gene (Table). 
Amino acid alignments of hMPV F gene were com-
pared to those of prototype isolates from the Netherlands
and Canada (data not shown). Cysteine residues were con-
served in all South African strains at positions 60 and 182.
Group-specific amino acid residue at positions 122, 135,
139, 167, 175, and 233 differentiated between groups A
and B. Further amino acid substitutions at various posi-
tions were exclusive to subgroups A1 (amino acids [aa] 61,
82, 143), A2 (aa 61, 143, 185), and subgroups B1 (aa 46,
143, 179) and B2 (aa 143). 
The predicted G ORF amino acid alignments of select-
ed South African strains with prototypes from the
Netherlands and Canada are shown in online Appendix
Figure (available at http://www.cdc.gov/ncidod/EID/
vol11no07/05-0050-appG.htm). Sequence variation due to
nucleotide substitutions and insertions led to variable
lengths in polypeptides, which ranged from 228 aa
residues (subgroup A2) to 240 aa residues (subgroup B2).
The hMPV G ORFs of subgroups A2 and B1 terminated at
the TAA codon, whereas the subgroup B2 isolates termi-
nated at the TAG codon. For both genetic groups A and B,
a cysteine residue was present in the intracellular domain.
In addition, group B isolates had a cysteine residue in the
extracellular domain except in 2 isolates (RSA/71/00 and
RSA/90/00). 
The region of the predicted G ORF sequenced in this
study had a high serine and threonine content
(30.7%–34.9% for group A, 30.6%–36.6% for group B
isolates). Proline content varied among the subgroups:
7.6%–9.0% for subgroup A2, 9.0%–9.9% for subgroup
A1, 7.8%–8.7%for subgroup B1, and 3.7%–5.2%, the low-
est content, for subgroup B2. Only 1 potential N-linked
glycosylation site was conserved at the junction of the
intracellular and transmembrane domains. 
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Figure. Neighbor-joining trees based on nucleotide sequences
from A) the partial F gene and B) the G gene open reading frame
from 61 South African human metapneumovirus (hMPV) isolates.
The trees were computed with MEGA version 2.1 with the
nucleotide Kimura 2-parameters. Bootstrap probabilities for 500
replicas are shown at the branch nodes. Only values of 70% to
100% are indicated. Isolates from South Africa are indicated by
RSA, followed by the isolate number and year (e.g., RSA/18/02).
The viruses from Canada (CAN97-83, hMPV13-00, CAN75-98,
and hMPV33-01) and the Netherlands (NL/1/00, NL/17/00,
NL/1/99, and NL/1/94) are prototypes from each subgroup.Discussion 
Genetic variability is a strong indicator of positive
selection and affects the ability of a virus to continue cir-
culating in a population. This variability poses a challenge
for future vaccine development that relies on worldwide
molecular epidemiologic studies. Recently, the hMPV G
gene was shown to be highly variable, particularly in the
extracellular domain, as a result of nucleotide substitu-
tions, insertions, and the use of alternative termination
transcription codons (17–19). Limited data have also indi-
cated that the 2 groups of hMPV cocirculate and that dif-
ferent subgroups may predominate from year to year
(2,4,17,21). 
We report on the largest community-based phylogenet-
ic study of hMPV for both surface glycoproteins and pro-
vide evidence on the circulation pattern of hMPV in a
single African community in 3 consecutive seasons. We
also provide evidence for the presence of multiple lineag-
es and genotypes of hMPV, as has been previously
observed for other respiratory viruses such as RSV
(26,27).
Phylogenetic analysis based on nucleotide sequences of
the F and G ORFs of the South African strains demonstrat-
ed the existence of 2 groups (A and B) and 2 subgroups (1
and 2). Using the criteria described for the existence of
multiple lineages for RSV (26), we demonstrated that mul-
tiple lineages of hMPV are circulating in South Africa;
however, these lineages need to be characterized at the
antigenic level and the clinical impact characterized. 
Strains from both hMPV groups cocirculated in South
Africa (Soweto, Johannesburg), but not all 4 subgroup
viruses cocirculated in a single year, evidence for a com-
plex circulation pattern that permits hMPV to evade preex-
isting immunity. In 2000, subgroups A2 and B2
cocirculated; in 2001, A1, A2, and B2 cocirculated; and in
2002, A1 and B1 cocirculated. A switch in predominant
subgroup from B2 to A1 was observed from the 2000 to
the 2001 epidemic. Subgroups A2 and B2 also declined in
subsequent years, and subgroup B1 emerged in 2002. The
absence of subgroup B1 in previous years may have been
due to preexisting community immunity rather than diag-
nostic assay limitations, as has been speculated (21).
Noting the trend in our results, we speculate that the emer-
gence of subgroup B1 virus may eventually have led to the
displacement of subgroup A1 as the dominant viral strain
in subsequent years. Similar findings in changes of the
dominant group of virus that emerges, fostered by a high
prevalence of preexisting community immunity to the
other major viral group, have been documented for RSV
(26–29). Our study, and another from the Southern
Hemisphere (21) showed a high prevalence of subgroup
A1 in 2001, a finding that suggests that specific strains
may coexist across geographic areas in a given epidemic.
hMPV in this study was sequenced directly from spec-
imens, which avoided any amino acid changes due to cell
culture adaptation of the viral surface proteins. Although
we only sequenced part of the F gene ORF, our results
concur with those of a previous study that sequenced the
full-length F gene and showed it to be highly conserved
(18). In contrast, a high degree of variation was observed
for the G gene at the nucleotide and amino acid levels.
The sequence variation in the G gene was due to
nucleotide substitutions, in-frame insertions, and the use
of alternative termination transcription codons. The in-
frame insertions we observed suggest that the nucleotide
changes previously seen (17) were not due to the passage
of hMPV in cell culture. Structural features of the G pro-
tein for both groups of South African strains were similar
to those observed by others (17,19) with a high serine-
threonine content (31%–36%) and variable numbers and
positions of N-linked glycosylation sites. The N-linked
glycosylation site at the junction between the intracellular
and transmembrane domains (position 30–32) was the
only conserved site among all groups. We also only
observed 1 conserved cysteine residue in the intracellular
domain, at amino acid position 27 of the G gene. The sec-
ond cysteine residue in the extracellular domain, at posi-
tion 65, previously reported to be present in all group B
isolates (17), was absent from 2 South African group B
isolates. Hydrophobicity plot data (data not shown) were
also similar for both groups A and B, and as reported by
others (17,19).
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strains sequenced in the study period and we performed
partial sequencing of the F gene, we showed that the circu-
lation pattern of hMPV is complex and that the circulation
of multiple lineages may suggest an attempt at evasion of
preexisting immunity. Our findings also suggest that
extended surveillance, over many years, may be necessary
to understand the molecular epidemiology of hMPV in any
given geographic area.
Mr. Ludewick is a doctoral student at the University of the
Witwatersrand in South Africa. His primary research interest is
the molecular epidemiology of respiratory pathogens.
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